BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24613269)

  • 1. Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization.
    Memon K; Kulik LM; Lewandowski RJ; Wang E; Wang J; Ryu RK; Hickey R; Vouche M; Baker T; Ganger D; Gates VL; Habib A; Mulcahy MF; Salem R
    J Vasc Interv Radiol; 2014 Jul; 25(7):1056-66. PubMed ID: 24613269
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Abouchaleh N; Gabr A; Ali R; Al Asadi A; Mora RA; Kallini JR; Mouli S; Riaz A; Lewandowski RJ; Salem R
    J Nucl Med; 2018 Jul; 59(7):1042-1048. PubMed ID: 29217739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Patients with Unresectable Hepatocellular Carcinoma Treated with Radioembolization.
    Sukato DC; Tohme S; Chalhoub D; Han K; Zajko A; Amesur N; Orons P; Marsh JW; Geller DA; Tsung A
    J Vasc Interv Radiol; 2015 Jun; 26(6):816-24.e1. PubMed ID: 25824315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.
    Gomaa AI; Al-Khatib A; Abdel-Razek W; Hashim MS; Waked I
    World J Gastroenterol; 2015 May; 21(18):5654-62. PubMed ID: 25987792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres.
    Kwok PC; Leung KC; Cheung MT; Lam TW; Szeto LT; Chou SQ; Chia NH; Tong CM; Yuen PK; Cheung CH; Law CK
    J Gastroenterol Hepatol; 2014 Nov; 29(11):1897-904. PubMed ID: 24734957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.
    Sangro B; Carpanese L; Cianni R; Golfieri R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Van Buskirk M; Bilbao JI; Ettorre GM; Salvatori R; Giampalma E; Geatti O; Wilhelm K; Hoffmann RT; Izzo F; Iñarrairaegui M; Maini CL; Urigo C; Cappelli A; Vit A; Ahmadzadehfar H; Jakobs TF; Lastoria S;
    Hepatology; 2011 Sep; 54(3):868-78. PubMed ID: 21618574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
    Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E
    J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of survival of patients with hepatocellular carcinoma: A comparative analysis of prognostic systems.
    Tannus RK; Almeida-Carvalho SR; Loureiro-Matos CA; Miziara-Gonzalez A; Salzedas-Netto AA; Szejnfeld D; D'Ippolito G; Pereira-Lanzoni V; Souza-Silva I
    PLoS One; 2018; 13(4):e0194922. PubMed ID: 29617435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
    Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
    Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival Analysis of Advanced HCC Treated with Radioembolization: Comparing Impact of Clinical Performance Status Versus Vascular Invasion/Metastases.
    Ali R; Gabr A; Abouchaleh N; Al Asadi A; Mora RA; Kulik L; Abecassis M; Riaz A; Salem R; Lewandowski RJ
    Cardiovasc Intervent Radiol; 2018 Feb; 41(2):260-269. PubMed ID: 28879621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced hepatocellular carcinoma: which staging systems best predict prognosis?
    Huitzil-Melendez FD; Capanu M; O'Reilly EM; Duffy A; Gansukh B; Saltz LL; Abou-Alfa GK
    J Clin Oncol; 2010 Jun; 28(17):2889-95. PubMed ID: 20458042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity.
    Padia SA; Kwan SW; Roudsari B; Monsky WL; Coveler A; Harris WP
    J Vasc Interv Radiol; 2014 Jul; 25(7):1067-73. PubMed ID: 24837982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population.
    Chan SL; Mo FK; Johnson PJ; Liem GS; Chan TC; Poon MC; Ma BB; Leung TW; Lai PB; Chan AT; Mok TS; Yeo W
    J Gastroenterol Hepatol; 2011 Feb; 26(2):340-7. PubMed ID: 21261725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic accuracy of staging systems in patients with primary liver cancer undergoing transarterial chemoembolization.
    Zhuge Y; Zhang F; Qiu Y; Li Z; Zhang J
    Hepatogastroenterology; 2013 May; 60(123):481-8. PubMed ID: 23635440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems.
    Shao YY; Lu LC; Lin ZZ; Hsu C; Shen YC; Hsu CH; Cheng AL
    Br J Cancer; 2012 Nov; 107(10):1672-7. PubMed ID: 23059748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
    Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
    Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience.
    Tohme S; Sukato D; Chen HW; Amesur N; Zajko AB; Humar A; Geller DA; Marsh JW; Tsung A
    J Vasc Interv Radiol; 2013 Nov; 24(11):1632-8. PubMed ID: 24160821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization.
    Abuodeh Y; Naghavi AO; Ahmed KA; Venkat PS; Kim Y; Kis B; Choi J; Biebel B; Sweeney J; Anaya DA; Kim R; Malafa M; Frakes JM; Hoffe SE; El-Haddad G
    World J Gastroenterol; 2016 Dec; 22(47):10406-10414. PubMed ID: 28058021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: a single-centre comparison amongst four different staging systems.
    Giannini E; Risso D; Botta F; Romagnoli P; Malfatti F; Fumagalli A; Testa E; Podestà E; Chiarbonello B; Polegato S; Testa R
    J Intern Med; 2004 Mar; 255(3):399-408. PubMed ID: 14871465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.